Shots:

• The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular- target and disease contexts
• Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will provide its hit identification services for Quantro’s anti-tumor projects
• Additionally- Evotec joins Boehringer Ingelheim Venture Fund as seed investor in Quantro and acquired equal minority stakes in Quantro

  Ref: Evotec | Image: Evotec